FLAIR, T1 contrast enhancement, MR perfusion, and FDG PET following hypofractionated stereotactic radiotherapy (HFSRT), bevacizumab (BEV), and temozolomide (TMZ) for glioblastoma (GBM) Meeting Abstract
| Authors: | Grommes, C.; Karimi, S.; Beal, K.; Chan, T. A.; Abrey, L. E.; Gutin, P. H.; Omuro, A. M. P. |
| Abstract Title: | FLAIR, T1 contrast enhancement, MR perfusion, and FDG PET following hypofractionated stereotactic radiotherapy (HFSRT), bevacizumab (BEV), and temozolomide (TMZ) for glioblastoma (GBM) |
| Meeting Title: | 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 29 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2011 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2011-05-20 |
| Language: | English |
| ACCESSION: | WOS:000208880301264 |
| DOI: | 10.1200/jco.2011.29.15_suppl.2048 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 2048 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
